Laura Carbone1, Petra Bůžková2, John Robbins3, Howard Fink4, Joshua Barzilay5, Rachel Elam1 and Carlos Isales1, 1Augusta University, Augusta, GA, 2University of Washington, Seattle, WA, 3UC Davis, Davis, CA, 4University of Minnesota, Minneapolis, MN, 5Kaiser Permanente, Atlanta, GA
Background/Purpose: Essential amino acids including tryptophan (trp) are building blocks for protein, and adequate protein intake is important for skeletal homeostasis. In experimental studies, trp increases bone formation. However, particularly with aging, trp is susceptible to oxidative modification, and oxidative stress is associated with osteoporosis. We sought to determine whether serum levels of trp and its oxidized and nonoxidized metabolites were risk factors for hip fracture and frailty.
Methods: We included participants within the Cardiovascular Health Study (CHS), a longitudinal study of community-dwelling adults aged 65 years and older from four U.S. sites. We selected participants from years 1992-1993 (year five of CHS) for whom stored serum was available and for whom there was complete information on relevant covariates. We included 131 individuals who sustained a hip fracture during the following twelve years of follow-up and 131 participants without an incident hip fracture over these following twelve years of follow- up (controls). Individuals were weighted by sex, race and hip fracture status to represent the whole CHS population at year 5. Measurements of trp and its metabolites were performed using liquid chromatograph-mass spectrometry analyses. Cox hazard models with robust standard errors were used to estimate the association of trp and its metabolites with hip fractures censoring at the first hip fracture event, death, loss of follow up or after 12 years of follow-up. Relative risk regression was done to evaluate the cross sectional association of trp and its metabolites with frailty using Freid's index with categories defined as frail vs. not frail and prefrail vs. frail. False discovery rate approach was used to adjust p values for multiple testing for secondary exposures. The primary exposure was trp; trp metabolites were secondary exposures.
Results: Higher serum levels of trp were significantly inversely associated with risk of incident hip fractures (Table 1) There were no statistically significant associations between the oxidized or nonoxidized products of trp with incident hip fractures (Tables 1 and 2) or with frailty status (frail vs. not frail) or with prefrail vs. not frail status (p >0.05 for both).
Conclusion: Trp, but not its metabolites, was significantly associated with less risk for incident hip fractures in older adults. Neither trp nor any of its metabolites was significantly associated with frailty. Prospective cohort studies are needed to estimate what difference in trp intake is associated with an absolute difference in incident hip fractures to design a future randomized clinical trial. Table 1. Association of Trp and its Metabolites with Hip Fractures
Table 2. Association of Oxidation Status of Trp Metabolites with Hip Fractures Disclosures: L. Carbone, None; P. Bůžková, None; J. Robbins, None; H. Fink, None; J. Barzilay, None; R. Elam, None; C. Isales, None.
.jpg)
Table 1. Association of Trp and its Metabolites with Hip Fractures
Table 2. Association of Oxidation Status of Trp Metabolites with Hip Fractures